By Christopher Morrison
By licensing co-promotion rights to the overactive bladder (OAB) treatment trospium (Sanctura) from Indevus Pharmaceuticals Inc. in April 2004, Croatian pharmaceutical firm Pliva DD catapulted itself into a...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?